GAUSH MEDITECH (02407) announced its interim results, with shareholders' net profit of 17.272 million yuan, a decrease of 54.52% year-on-year.

GAUSH MEDITECH (02407) announced its mid-term performance for 2026, reporting revenue of 595 million yuan, a year-on-year decrease of 8.9%. The company's profit attributable to shareholders was 17.272 million yuan, a decrease of 54.52% compared to the previous year; earnings per share were 0.12 yuan. The announcement stated that the decline in revenue from the group's distribution products was influenced by multiple adverse factors, including changes in market demand structure guided by national policies and the termination of overseas partnerships for femtosecond laser-assisted cataract surgery products. However, under pressure, the group's proprietary product revenue achieved a growth of 4.6%, aligning with the group's development strategy. In the second half of 2026, it is expected that several self-developed products will enter mass production and be launched, driving continuous revenue growth and contributing to the overall improvement of the group's performance.